

## Kyprolis - (60 mg/Vial; Powder, Intravenous)

<b>Generic Name</b>	Carfilzomib	<b>Innovator</b>	Onyx Pharma
<b>Dosage</b>	60 mg/Vial; Powder, Intravenous	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	More Than 5	<b>Known Para IV Filers</b>	More Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	None
<b>Indication</b>	Indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Kyprolis - (30mg/vial, powder, intravenous)

<b>Generic Name</b>	Carfilzomib	<b>Innovator</b>	Onyx Pharma
<b>Dosage</b>	30mg/vial, powder, intravenous	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	More Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Kyprolis - (10 mg/vial; Powder, Intravenous)

<b>Generic Name</b>	Carfilzomib	<b>Innovator</b>	Onyx Pharma
<b>Dosage</b>	10 mg/vial; Powder, Intravenous	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	None
<b>Indication</b>	Kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.